Kansas Bioscience Authority

Advanced Animal Diagnostics, Inc. specializes in the research, development, and commercialization of on-farm diagnostic tools aimed at the early detection of subclinical mastitis in dairy cows. Founded in 2001 and based in Durham, North Carolina, the company offers innovative products such as the QScout Farm Lab, an analyzer system that detects infections before visible symptoms occur, and the QScout Milk Leukocyte Differential rapid test, which identifies and differentiates leukocytes in milk to facilitate early mastitis detection. Additionally, Advanced Animal Diagnostics provides the QuickSmear slide for animal research and the SCC+ System for timely mastitis diagnosis. The company's solutions focus on enhancing the management of disease states and improving the reproductive, nutritional, and overall health of production animals, serving veterinarians and livestock producers to promote healthier and more productive animal care.

Flow Forward Medical is a company focused on enhancing vascular access sites to improve post-surgery success rates, particularly for patients undergoing hemodialysis. Founded in 2014 and headquartered in Olathe, Kansas, the company has developed the Arteriovenous Fistula Eligibility (AFE) System, which is a small, temporary external blood pump. This innovative device is designed to stimulate flow-mediated dilation of veins, thereby increasing the eligibility of patients for arteriovenous fistula (AVF) procedures and improving their surgical outcomes. By facilitating the establishment of reliable AVFs, Flow Forward Medical aims to reduce morbidity and mortality rates among hemodialysis patients and lower the overall costs associated with their care.

Innara Health, Inc. is a company focused on developing innovative neonatal care technologies aimed at improving the health and development of preterm and full-term infants, as well as children with developmental needs. The company is best known for its NTrainer System, a medical device designed to assist with the feeding of premature infants by promoting non-nutritive sucking skills and enhancing feeding outcomes. This device plays a crucial role in developmental feeding programs, allowing infants to engage in early and frequent nipping opportunities that help coordinate their suck, swallow, and breathe functions. Innara Health serves a wide range of stakeholders, including hospitals, neonatal intensive care units, clinicians, infants, children, and their families, with the goal of improving the quality of life for these vulnerable populations. Founded in 2006 and based in Olathe, Kansas, the company was previously known as KCBioMedix, Inc. before rebranding in 2013.

Artio Medical, Inc. is a medical device company focused on developing and commercializing catheter-based solutions for cardiovascular diseases. Based in Olathe, Kansas, the company specializes in endovascular devices designed for embolization of vessels, aneurysms, and other vascular structures. Its product offerings include Solus Gold and Solus Flex, both embolization devices featuring unique delivery systems, as well as Aneura and Endura, which combine coils and accessory balloons for the immediate occlusion of saccular and cerebral aneurysms, respectively. Artio Medical was founded in 2011 and was previously known as Metactive Medical, Inc. before rebranding in February 2020. The company operates as a subsidiary of Novita Therapeutics, LLC, and its innovations aim to enhance the speed and safety of vascular occlusion procedures for physicians.

Advanced Animal Diagnostics, Inc. specializes in the research, development, and commercialization of on-farm diagnostic tools aimed at the early detection of subclinical mastitis in dairy cows. Founded in 2001 and based in Durham, North Carolina, the company offers innovative products such as the QScout Farm Lab, an analyzer system that detects infections before visible symptoms occur, and the QScout Milk Leukocyte Differential rapid test, which identifies and differentiates leukocytes in milk to facilitate early mastitis detection. Additionally, Advanced Animal Diagnostics provides the QuickSmear slide for animal research and the SCC+ System for timely mastitis diagnosis. The company's solutions focus on enhancing the management of disease states and improving the reproductive, nutritional, and overall health of production animals, serving veterinarians and livestock producers to promote healthier and more productive animal care.

Health Outcomes Sciences LLC, established in 2005 and based in Overland Park, Kansas, specializes in providing information technology solutions to enhance healthcare delivery. The company focuses on translating advancements in clinical research into practical, evidence-based tools for physicians, patients, and healthcare organizations. Its flagship product is the ePRISM platform, which facilitates the creation of predictive models as Web-based tools and XML Web services. These models can be updated in real-time and are used across various applications such as clinical decision support, shared medical decision-making, patient education, and personalized educational materials. Additionally, Health Outcomes Sciences offers readmission models to estimate risk-standardized days that cause readmission rates for patients admitted with specific conditions like PCI, acute myocardial infarction, COPD, heart failure, and pneumonia. The company's interdisciplinary team comprises physicians, outcomes researchers, and IT experts who prioritize creating intuitive, responsive user interfaces that integrate seamlessly into clinical workflows.

Flow Forward Medical is a company focused on enhancing vascular access sites to improve post-surgery success rates, particularly for patients undergoing hemodialysis. Founded in 2014 and headquartered in Olathe, Kansas, the company has developed the Arteriovenous Fistula Eligibility (AFE) System, which is a small, temporary external blood pump. This innovative device is designed to stimulate flow-mediated dilation of veins, thereby increasing the eligibility of patients for arteriovenous fistula (AVF) procedures and improving their surgical outcomes. By facilitating the establishment of reliable AVFs, Flow Forward Medical aims to reduce morbidity and mortality rates among hemodialysis patients and lower the overall costs associated with their care.

Aratana Therapeutics, Inc. is a biopharmaceutical company dedicated to developing and commercializing therapeutics for dogs and cats in the United States. Founded in 2010 and headquartered in Leawood, Kansas, the company focuses on addressing unmet medical needs in companion animal care through high-quality medicines. Its product portfolio includes various therapeutics, such as NOCITA for post-operative pain management in dogs, ENTYCE for appetite stimulation, and GALLIPRANT for pain and inflammation associated with osteoarthritis. Aratana is also advancing treatments for conditions like osteosarcoma in dogs and a range of therapies for cats, including a specialized formulation for pain management and treatments for feline herpes virus-induced conditions. The company has established collaboration agreements with other health organizations to enhance the development and commercialization of its products.

Aratana Therapeutics, Inc. is a biopharmaceutical company dedicated to developing and commercializing therapeutics for dogs and cats in the United States. Founded in 2010 and headquartered in Leawood, Kansas, the company focuses on addressing unmet medical needs in companion animal care through high-quality medicines. Its product portfolio includes various therapeutics, such as NOCITA for post-operative pain management in dogs, ENTYCE for appetite stimulation, and GALLIPRANT for pain and inflammation associated with osteoarthritis. Aratana is also advancing treatments for conditions like osteosarcoma in dogs and a range of therapies for cats, including a specialized formulation for pain management and treatments for feline herpes virus-induced conditions. The company has established collaboration agreements with other health organizations to enhance the development and commercialization of its products.

Innara Health, Inc. is a company focused on developing innovative neonatal care technologies aimed at improving the health and development of preterm and full-term infants, as well as children with developmental needs. The company is best known for its NTrainer System, a medical device designed to assist with the feeding of premature infants by promoting non-nutritive sucking skills and enhancing feeding outcomes. This device plays a crucial role in developmental feeding programs, allowing infants to engage in early and frequent nipping opportunities that help coordinate their suck, swallow, and breathe functions. Innara Health serves a wide range of stakeholders, including hospitals, neonatal intensive care units, clinicians, infants, children, and their families, with the goal of improving the quality of life for these vulnerable populations. Founded in 2006 and based in Olathe, Kansas, the company was previously known as KCBioMedix, Inc. before rebranding in 2013.

Osteogenix is a therapeutic products company with novel products for the large and rapidly growing area of bone repair and bone growth. Osteogenix was founded in 2005 to clinically develop and commercialize the osteo-pharmacologic platform discovered and patented by Dr. Mundy and his associates. Osteogenix assembled an outstanding team of expert advisors, many of whom have been principal investigators in key orthobiologics trials.

IGXBio, Inc. is a biotechnology company focused on developing advanced DNA immunotherapies specifically targeting HIV infection. The company utilizes a proprietary DNA composition that synthetically mimics the HIV virus, aiming to elicit an immune response that is less toxic compared to existing AIDS drug treatments. This innovative approach seeks to enhance the efficacy of HIV treatment while minimizing the adverse effects typically associated with conventional therapies, ultimately enabling healthcare providers to better manage and reduce HIV infections.

VasoGenix Pharmaceuticals, Inc., is developing intravenous (IV) and controlled release drug treatments for addressing Heart Failure ("HF") and other cardiac diseases in order to reduce the recurrence of these diseases and their resulting hospital and medical costs. VasoGenix is initially focusing on a major unmet critical need in Acute Decompensated Heart Failure ("ADHF"), when the symptoms of HF become severe enough to require hospitalization.